Valuation: Lakefront Biotherapeutics NV

Market Cap 1.59B 1.83B 1.47B 1.36B 2.56B 175B 2.61B 17.46B 6.84B 86.69B 6.87B 6.72B 292B P/E 2026 *
-11.3x
P/E 2027 * -8.53x
Enterprise Value -395M -455M -367M -338M -637M -43.43B -649M -4.34B -1.7B -21.57B -1.71B -1.67B -72.54B EV / Sales 2026 *
-27.7x
EV / Sales 2027 * -8.8x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lakefront Biotherapeutics NV

1 day+0.41%
1 week-1.22%
Current month-7.70%
1 month-6.92%
6 months-16.26%
Current year-13.57%
1 week 23.82
Extreme 23.82
25.26
1 month 23.82
Extreme 23.82
27.12
Current year 22.62
Extreme 22.62
30.72
1 year 22.62
Extreme 22.62
32.74
3 years 20
Extreme 20
40.26
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Date Insider Type Main position Quantity % Market Cap.
1/28/26 Buy

Director

137 0.0002%
1/28/26 Buy

Director

375 0.0006%
1/28/26 Free

General Counsel

235,000 0.3566%
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%-1.22%-16.15%-36.45% 1.83B
+0.93%+4.93%+0.52%+13.82% 49.37B
-3.95%+14.70%+24.15%+5.15% 39.14B
+6.22%+1.81%+419.17%+647.45% 40.85B
-1.57%-1.44%+7.38%+43.06% 35.81B
+5.56%+11.70%+11.64%+51.50% 30.5B
-0.39%-0.63% - - 16.55B
-1.13%-4.54%+32.10%+126.95% 16.14B
-7.10%-2.81%-8.80%-34.35% 12.77B
-0.17%+3.13%+1.72%+9.43% 13.71B
Average -0.12%+5.03%+52.42%+91.84% 25.67B
Weighted average by Cap. +0.56%+6.93%+79.60%+133.76%

Financials

2026 *2027 *
Net sales 14.24M 16.39M 13.22M 12.2M 22.97M 1.57B 23.39M 157M 61.3M 777M 61.57M 60.22M 2.61B 46.09M 53.06M 42.8M 39.47M 74.35M 5.07B 75.7M 507M 198M 2.52B 199M 195M 8.46B
Net income -811M -933M -753M -694M -1.31B -89.1B -1.33B -8.91B -3.49B -44.25B -3.5B -3.43B -149B -238M -274M -221M -204M -384M -26.14B -391M -2.61B -1.02B -12.98B -1.03B -1.01B -43.65B
Net Debt -1.98B -2.28B -1.84B -1.7B -3.2B -218B -3.26B -21.8B -8.54B -108B -8.57B -8.39B -364B -1.99B -2.3B -1.85B -1.71B -3.22B -219B -3.27B -21.92B -8.58B -109B -8.62B -8.43B -366B
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
452
Date Price Change Volume
26-07-31 24.20 +0.41% 14,206
26-07-30 €24.10 -1.79% 87,672
26-07-29 €24.54 -0.65% 61,709
26-07-28 €24.70 -0.40% 56,583
26-07-27 €24.80 +1.22% 70,144
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
24.10EUR
Average target price
30.28EUR
Spread / Average Target
+25.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LKFT Stock